Brookstone Capital Management - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 425 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.2%.

Quarter-by-quarter ownership
Brookstone Capital Management ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$2,160,029
-2.4%
60,336
-0.1%
0.05%
+4.4%
Q2 2023$2,212,397
+1.7%
60,4150.0%0.04%
+7.1%
Q1 2023$2,174,940
-35.0%
60,415
+0.2%
0.04%
-38.2%
Q4 2022$3,345,999
+30.2%
60,3100.0%0.07%
+15.3%
Q3 2022$2,569,000
-17.8%
60,310
-0.1%
0.06%
-14.5%
Q2 2022$3,125,000
+25.2%
60,345
+0.1%
0.07%
+40.8%
Q1 2022$2,496,000
+11.0%
60,3100.0%0.05%
+25.6%
Q4 2021$2,249,000
+1.1%
60,3100.0%0.04%
-2.5%
Q3 2021$2,225,000
-17.8%
60,3100.0%0.04%
-18.4%
Q2 2021$2,708,00060,3100.05%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2022
NameSharesValueWeighting ↓
Third Security, LLC 1,129,551$47,091,0006.38%
First Light Asset Management, LLC 2,011,350$83,853,0005.56%
TRAN CAPITAL MANAGEMENT, L.P. 1,353,208$56,415,0005.03%
SNYDER CAPITAL MANAGEMENT L P 2,920,860$121,771,0003.50%
DOHENY ASSET MANAGEMENT /CA 120,028$5,004,0003.39%
SILVERARC CAPITAL MANAGEMENT, LLC 104,945$4,375,0002.39%
Redwood Investments, LLC 542,764$22,628,0001.99%
Kent Lake Capital LLC 85,000$3,544,0001.44%
Lisanti Capital Growth, LLC 263,460$10,984,0001.41%
Bellevue Group AG 3,011,966$125,569,0001.33%
View complete list of HALOZYME THERAPEUTICS INC shareholders